Genetics, Mechanisms and Clinical Phenotypes of Arrhythmogenic Cardiomyopathy

致心律失常性心肌病的遗传学、机制和临床表型

• 批准号: 8920265
• 负责人: FRANK I MARCUS
• 金额: $ 7.97万
• 依托单位: CINCINNATI CHILDRENS HOSP MED CTR
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-08-23 至 2017-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8920265
• 关键词: Adverse event; Advisory Committees; Affect; Age of Onset; Apoptotic; Arrhythmia; Arrhythmogenic Right Ventricular Dysplasia; Binding; Bioinformatics; Biological Markers; Cardiac; Cardiomyopathies; Cells; Child; Clinical; Congenital Heart Defects; Connexin 43; DLG1 gene; Data; Databases; Defect; Desmosomes; Diagnostic; Diagnostic Procedure; Diagnostic tests; Dilated Cardiomyopathy; Disease; Disease Progression; Environmental Risk Factor; Epigenetic Process; Event; Failure; Familial disease; Family; Family member; Funding; Future; Gene Mutation; Gene-Modified; Genes; Genetic; Genomics; Genotype; Goals; Grant; Health; Heart failure; Immunohistochemistry; Individual; Inflammation; Inflammation Mediators; Inherited; Intercalated disc; Intercellular Junctions; Knowledge; Lead; Left; Life; Link; Measures; Mutation; Myocardial; Myocardium; Myopathy; National Heart, Lung, and Blood Institute; Outcome; Pathologic; Pathway interactions; Patients; Phenotype; Play; Prevention; Preventive; Proteins; Publishing; Registries; Resolution; Resources; Risk; Role; Severity of illness; Signal Pathway; Specimen; Stratification; Sudden Death; Systems Biology; Technology; Testing; Transcript; Variant; Ventricular; Work; base; cell injury; clinical phenotype; cohort; diagnostic accuracy; exome; genetic variant; high throughput technology; improved; next generation; novel; plakoglobin; prevent; repository; stoichiometry; trafficking; treatment strategy

DESCRIPTION (provided by applicant): Arrhythmogenic ventricular cardiomyopathies (AVCs) are clinically and genetically heterogeneous heart muscle disorders characterized by frequent, often life-threatening arrhythmias that typically precede structural remodeling of the heart muscle or clinical evidence of heart failure. In the majority of subjects having these inherited, family transmitted diseases the underlying cause is not known. AVCs include arrhythmogenic RV cardiomyopathy (ARVC), the more recently described arrhythmogenic LV cardiomyopathy (ALVC), and a group of dilated cardiomyopathies in which arrhythmias are prominent (aDCM). While these heart abnormalities may appear unrelated when compared by traditional clinical and pathological criteria, recent evidence indicates they share common genetic causes and result from disruption of the same "final common pathways". Mutations in genes encoding desmosomal proteins or desmosome-interacting proteins appear to play a major role in causing ARVC and ALVC. Recent evidence suggests some common genetic causes between ALVC and aDCM (and therefore ARVC), as well as mechanistic links between mutations in genes encoding Z-disk proteins and desmosomal disruption in aDCM. Recently, Saffitz and colleagues have correlated cell biologic myocardial biomarkers with genetic and clinical/histopathologic findings of ARVC and ALVC and suggests these findings, as well as abnormalities in cardiac inflammatory mediators, are diagnostic of AVCs. In addition, we have shown that Wnt signaling pathways are impaired by changing ?-catenin stoichiometry, impairing forward trafficking of critical proteins to the intercalated disk by mechanisms involving SAP97 and ROCK/ microtubular transport, and activates apoptotic pathways, mechanisms linking cell injury and arrhythmias in AVCs. AVCs result from a consistent failure of critical proteins (Cx43, Nav1.5, Kir2.1) to localize to intercalated disks due to defects in forward trafficking. Despite this progress in understanding the origin and progression of classical ARVC, however, many questions remain unresolved. First, disease-causing genes are identified in only ~30-50 % of patients. Second, multiple mutations (compound and digenic heterozygosity) are emerging as frequent associations, adding more complexity to understanding the genetic basis of ARVC. Third, inter- and intra-familial variability is not explained by current knowledge, suggesting more complexity, potentially involving currently unknown epigenetic and environmental factors. Fourth, the proportion of ALVC due to desmosomal defects is unknown but its clinical identification is increasing. Fifth, much more work needs to be done to characterize aDCM in view of genetic and "final common pathway" links to ALVC. In this proposal we will combine well-established, consistent and precise diagnostic approach developed in our previous ARVC Registry grant (published as the "Modified Task Force Criteria") with a comprehensive primary genotyping approach and search for genetic modifiers using next generation high-throughput genetic discovery technologies and biomarker analysis to identify the genetic basis of all forms of AVCs (ARVC, ALVC, and aDCM), to establish detailed mechanistic and diagnostic understanding, and correlate these findings with clinical phenotypes to improve risk-stratification and better predict adverse events. We will test the general hypothesis that mutations in genes encoding "final common pathway" proteins of the desmosome/cell-cell junction pathway (or its binding partners), leads to destabilization of desmosomes and disruption of the intercalated disk and inflammation, and impairs Wnt signaling pathways by changing the stoichiometry of ?-catenin. This impairs forward trafficking of critical proteins to the intercalated disk by mechanisms involving SAP97 and ROCK/ microtubular transport. It also activates apoptotic pathways, thus providing a mechanism linking cell injury and arrhythmias in AVCs. The Specific Aims are: 1) To identify new genes causing ARVC, ALVC, and aDCM; 2A) To evaluate genotype-phenotype associations in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC); 2B) To evaluate patients with suspected arrhythmogenic left ventricular cardiomyopathy (ALVC) and arrhythmogenic dilated cardiomyopathy (aDCM) and to evaluate genotype-phenotype associations in patients with ALVC and aDCM; and 3) To discover new biomarkers in AVCs and critically assess their value in improving the sensitivity and accuracy of diagnosis and predicting arrhythmias or other manifestations of disease.

描述（由申请人提供）： 致心律失常性心室心肌病（Arrhythmogenic ventricular cardiomyopathies，AVC）是一种临床和遗传异质性心肌疾病，其特征是频繁发生、通常危及生命的心律失常，通常发生在心肌结构重塑或心力衰竭的临床证据之前。在大多数患有这些遗传性、家族传播疾病的受试者中，根本原因尚不清楚。AVC包括致心律失常性RV心肌病（ARVC）、最近描述的致心律失常性LV心肌病（ALVC）和一组心律失常突出的扩张型心肌病（aDCM）。虽然这些心脏异常在传统的临床和病理标准比较时可能看起来不相关，但最近的证据表明它们具有共同的遗传原因，并且是由相同的“最终共同途径”中断引起的。编码桥粒蛋白或桥粒相互作用蛋白的基因突变似乎在引起ARVC和ALVC中起主要作用。最近的证据表明，ALVC和aDCM（因此ARVC）之间存在一些共同的遗传原因，以及编码Z盘蛋白的基因突变和aDCM桥粒破坏之间的机制联系。最近，Saffitz及其同事将细胞生物学心肌生物标志物与ARVC和ALVC的遗传和临床/组织病理学结果相关联，并表明这些结果以及心脏炎症介质的异常可以诊断AVC。此外，我们已经表明，Wnt信号通路受损的变化？连环蛋白化学计量学，通过涉及SAP 97和ROCK/微管转运的机制损害关键蛋白向闰盘的正向运输，并激活凋亡途径，这是连接AVC中细胞损伤和心律失常的机制。由于前向运输的缺陷，关键蛋白质（Cx43，Nav1.5，Kir2.1）定位于闰盘的一致失败导致了AVC。然而，尽管在理解经典ARVC的起源和进展方面取得了进展，但许多问题仍未解决。首先，致病基因仅在约30- 50%的患者中被鉴定。其次，多个突变（复合和双基因杂合性）正在成为频繁的关联，增加了理解ARVC遗传基础的复杂性。第三，目前的知识不能解释家族间和家族内的变异性，这表明更复杂，可能涉及目前未知的表观遗传和环境因素。第四，由于桥粒缺陷导致的ALVC的比例尚不清楚，但其临床识别正在增加。第五，鉴于与ALVC的遗传和“最终共同途径”联系，需要做更多的工作来表征aDCM。在本提案中，我们将结合联合收割机在我们之前的ARVC登记研究资助中开发的成熟、一致和精确的诊断方法（发表为“Modified Task Force Criteria”），采用全面的初级基因分型方法，并使用下一代高通量遗传发现技术和生物标志物分析来寻找遗传修饰剂，以确定所有形式的AVC的遗传基础（ARVC，ALVC和aDCM），以建立详细的机制和诊断理解，并将这些发现与临床表型相关联，以改善风险分层并更好地预测 不良事件。我们将测试一般假设，即编码桥粒/细胞-细胞连接途径（或其结合伴侣）的“最终共同途径”蛋白质的基因突变，导致桥粒不稳定和闰盘和炎症的破坏，并通过改变？连环蛋白。这损害了通过涉及SAP 97和ROCK/微管转运的机制将关键蛋白向前运输到闰盘。它还激活细胞凋亡途径，从而提供了一种机制，连接细胞损伤和心律失常的AVC。具体目标是：1）鉴定引起ARVC、ALVC和aDCM的新基因; 2A）评估致瘤性右心室心肌病（ARVC）患者的基因型-表型关联; 2B）评估疑似致瘤性左心室心肌病（ALVC）和致瘤性扩张型心肌病（aDCM）患者，并评估ALVC和aDCM患者的基因型-表型关联;发现新的AVCs生物标志物，并对其在提高诊断和预测AVCs的敏感性和准确性方面的价值进行评估 心律失常或其他疾病表现。